Etoricoxib is safe and effective in preventing heterotopic ossification after primary total hip arthroplasty.
Etoricoxib
Heterotopic ossification
Total hip arthroplasty
Undesirable side effects
Journal
Journal of orthopaedic surgery and research
ISSN: 1749-799X
Titre abrégé: J Orthop Surg Res
Pays: England
ID NLM: 101265112
Informations de publication
Date de publication:
27 Feb 2021
27 Feb 2021
Historique:
received:
02
02
2021
accepted:
10
02
2021
entrez:
28
2
2021
pubmed:
1
3
2021
medline:
8
9
2021
Statut:
epublish
Résumé
Heterotopic ossifications are a common complication after total hip arthroplasty. Low-dose radiation therapy and non-steroidal anti-inflammatory drugs have proven to effectively reduce the rate of heterotopic ossification after total hip arthroplasty. However, a low number of studies describe an equal efficiency of etoricoxib. This work shows first results on the examination of a larger group with 194 subjects to analyze efficiency and rate of side effects under treatment with etoricoxib. Clinical examinations were performed the day before surgery and after at least 12 months. The survey of clinical and functional outcome was done with Harris Hip Score (HHS). Conventional antero-posterior radiographs and second plane in frog leg position were assessed. In total, 14 undesirable side effects (7.4%) and only four early terminations of therapy (2.1%) were documented. A complete 1-year follow-up examination including radiographs could be done in 143 subjects (79.4%). Only 28 subjects (19.6%) developed heterotopic ossifications from which 92.9% were classified in type 1 and 7.1% in type 2 using the method described by Brooker. The results do not show correlations with body mass index, extended treatment (more than ten days), or clinical and functional outcome (measured by "Harris Hip Score"). However, male subjects show a significantly higher rate of heterotopic ossifications. The investigations presented in this study confirm a good efficiency of etoricoxib for the prevention of heterotopic ossifications in comparison with classical methods such as radiation or drug therapy and show a low rate of undesirable side effects.
Sections du résumé
BACKGROUND
BACKGROUND
Heterotopic ossifications are a common complication after total hip arthroplasty. Low-dose radiation therapy and non-steroidal anti-inflammatory drugs have proven to effectively reduce the rate of heterotopic ossification after total hip arthroplasty. However, a low number of studies describe an equal efficiency of etoricoxib. This work shows first results on the examination of a larger group with 194 subjects to analyze efficiency and rate of side effects under treatment with etoricoxib.
METHODS
METHODS
Clinical examinations were performed the day before surgery and after at least 12 months. The survey of clinical and functional outcome was done with Harris Hip Score (HHS). Conventional antero-posterior radiographs and second plane in frog leg position were assessed.
RESULTS
RESULTS
In total, 14 undesirable side effects (7.4%) and only four early terminations of therapy (2.1%) were documented. A complete 1-year follow-up examination including radiographs could be done in 143 subjects (79.4%). Only 28 subjects (19.6%) developed heterotopic ossifications from which 92.9% were classified in type 1 and 7.1% in type 2 using the method described by Brooker. The results do not show correlations with body mass index, extended treatment (more than ten days), or clinical and functional outcome (measured by "Harris Hip Score"). However, male subjects show a significantly higher rate of heterotopic ossifications.
CONCLUSIONS
CONCLUSIONS
The investigations presented in this study confirm a good efficiency of etoricoxib for the prevention of heterotopic ossifications in comparison with classical methods such as radiation or drug therapy and show a low rate of undesirable side effects.
Identifiants
pubmed: 33639986
doi: 10.1186/s13018-021-02297-6
pii: 10.1186/s13018-021-02297-6
pmc: PMC7912510
doi:
Substances chimiques
Cyclooxygenase 2 Inhibitors
0
Etoricoxib
WRX4NFY03R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
163Références
Acta Orthop Belg. 2000 Apr;66(2):174-80
pubmed: 10842879
J Bone Joint Surg Br. 2003 Jul;85(5):700-5
pubmed: 12892193
J Arthroplasty. 1988;3(3):229-34
pubmed: 3141590
Arch Orthop Trauma Surg. 1998;117(6-7):337-40
pubmed: 9709846
Int Orthop. 2013 Aug;37(8):1629
pubmed: 23736968
J Bone Joint Surg Am. 1973 Dec;55(8):1629-32
pubmed: 4217797
J Bone Joint Surg Am. 1981 Feb;63(2):201-8
pubmed: 6780568
Int Orthop. 2011 Jan;35(1):3-8
pubmed: 19830425
ANZ J Surg. 2003 Jun;73(6):422-6
pubmed: 12801342
J Orthop Trauma. 1993;7(1):33-8
pubmed: 8433197
Int Orthop. 2016 Apr;40(4):673-80
pubmed: 26728611
J Bone Joint Surg Am. 1969 Jun;51(4):737-55
pubmed: 5783851
Clin Orthop Relat Res. 1991 Feb;(263):49-58
pubmed: 1899637
J Arthroplasty. 2014 Feb;29(2):390-2
pubmed: 23927909
J Bone Joint Surg Br. 1990 Jan;72(1):2-8
pubmed: 2298788
Int Orthop. 2013 Apr;37(4):583-7
pubmed: 23359100
Acta Orthop. 2007 Feb;78(1):95-8
pubmed: 17453399